Innovations Shaping the Future of Viral Vector Manufacturing

Today, viral vector manufacturing faces three main bottlenecks: scalability, regulatory complexity and supply chain continuity. Technically, scaling from research to GMP production while maintaining yield and quality is still challenging, especially for complex vector platforms.

Regulatory frameworks are evolving rapidly, requiring continuous adaptation and harmonization across regions.

Logistically, sourcing critical materials and maintaining cold-chain integrity add pressure on timelines and costs.

At ReiThera, we tackle these challenges by developing robust, scalable processes, strengthening our quality systems and implementing integrated logistics to ensure efficiency from development to commercial manufacturing. 

ReiCell-AAV is ReiThera’s proprietary suspension cell line developed specifically for high-yield AAV vector production. It was designed to overcome some of the key limitations of traditional adherent or HEK293-based systems, such as scalability constraints and process variability.

The platform offers several advantages: it supports robust growth in suspension, enabling seamless scale-up from laboratory to large bioreactor volumes; it provides consistently high vector productivity across multiple serotypes; and it is fully compatible with serum-free, chemically defined media, which improves reproducibility and regulatory compliance.

Combined with ReiThera’s optimized upstream and downstream processes, ReiCell-AAV delivers a more efficient, scalable and GMP-ready solution for gene therapy developers aiming to accelerate clinical and commercial manufacturing. 

There are two main advantages in using a NHP vector, namely the manufacturability and the immunological potency.

From a manufacturing standpoint, Ad5-based vectors share sequence homology with the packaging cell line, which can lead to the generation of replication-competent adenoviruses (RCA) and potentially result in the rejection of manufactured batches. GRAd32 genomic sequences reduce the risk of RCA formation during production in HEK293 cells, providing a critical biosafety and process reliability advantage.

In addition, GRAd32 is supported by a validated analytical platform, which ensures full control over product quality and regulatory compliance at both small (pre-clinical) and large (clinical) scale. This end-to-end ownership strengthens process robustness and scalability across development and commercial manufacturing.

From a potency standpoint, human adenoviral vectors, such as Ad5, are well known for their strong immunogenicity; however, the widespread pre-existing immunity to Ad5 in humans can markedly reduce their potency.

In contrast, NHP-derived adenoviral vectors, including the gorilla-derived GRAd32, overcome these limitations due to their low seroprevalence in humans, thereby preserving full immunological potency.

Traditional vaccinology has primarily aimed to prevent infection through the induction of neutralizing antibodies. However, the COVID-19 pandemic has clearly shown that vaccine efficacy does not necessarily depend on preventing infection – which is largely antibody-mediated – but also on preventing severe disease, a protection mainly driven by CD8⁺ T cell immunity.  

In this context, GRAd32 fits well into emerging vaccine strategies, as it consistently induces potent, broad and durable CD8⁺ T cell responses, potentially superior not only to other adenoviral platforms but also to mRNA-based vaccines.

Looking ahead in the gene therapy field, the low seroprevalence and reduced liver tropism of GRAd32 make it a promising vector for in vivo applications targeting disseminated diseases, while avoiding the liver sequestration typically associated with Ad5-based vectors. 

At ESGCT 2025, we saw strong momentum toward next-generation viral vector platforms designed for scalability, manufacturability and patient accessibility. There’s a clear shift toward process intensification and the adoption of stable producer cell lines to make AAV and adenoviral manufacturing more efficient.

What stood out most is that innovation in viral vectors is increasingly focused not only on scientific progress, but on building scalable and sustainable systems that can deliver advanced therapies to patients faster.  

I believe the next wave of viral vector manufacturing will be defined by three major innovations: scalability, precision and accessibility.

First, we will see a strong shift toward scalable and cost-efficient production systems, driven by the need to make gene therapies and advanced vaccines more accessible. This includes stable producer cell lines, cell-free or continuous manufacturing and automation with real-time process monitoring to ensure consistency and reduce cost of goods.

Second, the integration of AI, ML and digital twins will profoundly reshape process development. AI can use large, multimodal datasets from manufacturing and analytical systems to predict optimal process parameters, detect deviations in real time and guide adaptive control strategies.

ML-based tools are already being used to optimize cell culture conditions, analyze metabolic patterns and forecast harvest points, while digital twins enable model-predictive control that reduces experimental burden and accelerates process understanding.

Finally, we can expect growing emphasis on platform flexibility and standardization, enabling manufacturing processes to be rapidly adapted from one product to another – much like what has occurred in mRNA vaccine production.

The introduction to this interview includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.